Potential disease trigger as a therapeutic option: infliximab for paradoxical reaction in tuberculosis of the central nervous system

BMJ Case Rep. 2021 Aug 2;14(8):e235511. doi: 10.1136/bcr-2020-235511.

Abstract

A 36-year-old man of central Asian origin was diagnosed with subacute disseminated tuberculosis. Initially, central nervous system involvement was suggested by an encephalopathic condition and MRI showing extensive basal and spinal meningitis. After initiation of anti-tuberculosis drugs and corticosteroid therapy, clinical and radiological deterioration of spinal damage was noted. We interpreted this in the context of a paradoxical reaction, which is suggested to be an overshooting inflammatory response after reconstitution of the immune system. Despite increased dosage of corticosteroids, a gradual worsening of gait ataxia over several weeks was noted. After administration of infliximab, the patient's condition progressively improved.

Keywords: TB and other respiratory infections; immunological products and vaccines; immunology; infection (neurology); meningitis.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Antitubercular Agents / therapeutic use
  • Central Nervous System
  • Humans
  • Immune Reconstitution Inflammatory Syndrome* / drug therapy
  • Infliximab / adverse effects
  • Tuberculosis, Miliary* / drug therapy

Substances

  • Adrenal Cortex Hormones
  • Antitubercular Agents
  • Infliximab